Review| Volume 15, ISSUE 1, P7-15, March 2016

Download started.


Maintenance Therapy in Colorectal Cancer: Moving the Artillery Down While Keeping an Eye on the Enemy

Published:August 22, 2015DOI:


      The survival improvement in metastatic colorectal cancer, achieved with more intensive chemotherapy regimens, has recently led clinicians to question the optimal duration of therapies and to consider the role of maintenance. Indeed, patients whose disease is controlled after induction chemotherapy may benefit from continuing a less intensive regimen in order to reinforce the results achieved with up-front treatment. In addition, the more favorable toxicity profile of maintenance approaches would ensure a better quality of life. After discussing the rationale and the difference of pursuing a maintenance strategy with chemotherapeutic and/or biologic agents, we present significant available data from the literature and comment on the current implications and future directions of maintenance therapy. The current roles of depotentiated treatment schedules, antiangiogenic compounds, epidermal growth factor receptor inhibitors, and novel targeted therapies are also reviewed. Finally, we address elements that may foster clinical and social debate on this topic, suggesting potential aspects that need to be further investigated.

      Graphical abstract

      Figure thumbnail fx1
      Graphical Abstract


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Colorectal Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Venook A.P.
        • Niedzwiecki D.
        • Lenz H.J.
        • et al.
        CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).
        J Clin Oncol. 2014; 32 (abstract LBA3)
        • Cremolini C.
        • Loupakis F.
        • Antoniotti C.
        • et al.
        FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
        Lancet Oncol. 2015; (pii: S1470-2045(15)00122-9)
        • Aprile G.
        • Lutrino S.E.
        • Ferrari L.
        • et al.
        Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients.
        World J Gastroenterol. 2013; 19: 8474-8488
        • Brenner H.
        • Kloor M.
        • Pox C.P.
        Colorectal cancer.
        Lancet. 2014; 383: 1490-1502
        • Giuliani F.
        • De Vita F.
        • Colucci G.
        • et al.
        Maintenance therapy in colon cancer.
        Cancer Treat Rev. 2010; 36: S42-S45
        • Simkens L.H.
        • Koopman M.
        • Punt C.J.
        Optimal duration of systemic treatment in metastatic colorectal cancer.
        Curr Opin Oncol. 2014; 26: 448-453
        • Seymour M.
        Conceptual approaches to metastatic disease.
        Ann Oncol. 2012; 23: x77-x80
        • Falcone A.
        • Ricci S.
        • Brunetti I.
        • et al.
        Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.
        J Clin Oncol. 2007; 25: 1670-1676
        • Marino D.
        • Leone F.
        • D'Avanzo F.
        • et al.
        Potentially resectable metastatic colorectal cancer: an individualized approach to conversion therapy.
        Crit Rev Oncol Hematol. 2014; 92: 218-226
        • Van Cutsem E.
        • Cervantes A.
        • Nordlinger B.
        • et al.
        • ESMO Guidelines Working Group
        Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.
        Ann Oncol. 2014; 25: iii1-iii9
        • Fidias P.M.
        • Dakhil S.R.
        • Lyss A.P.
        • et al.
        Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non–small-cell lung cancer.
        J Clin Oncol. 2009; 27: 591-598
        • Paz-Ares L.G.
        • de Marinis F.
        • Dediu M.
        • et al.
        PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non–small-cell lung cancer.
        J Clin Oncol. 2013; 31: 2895-2902
        • Gligorov J.
        • Doval D.
        • Bines J.
        • et al.
        Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial.
        Lancet Oncol. 2014; 15: 1351-1360
        • Burger R.A.
        • Brady M.F.
        • Bookman M.A.
        • et al.
        Incorporation of bevacizumab in the primary treatment of ovarian cancer.
        N Engl J Med. 2011; 365: 2473-2483
        • Perren T.J.
        • Swart A.M.
        • Pfisterer J.
        • et al.
        A phase 3 trial of bevacizumab in ovarian cancer.
        N Engl J Med. 2011; 365: 2484-2496
        • Troiani T.
        • Martinelli E.
        • Napolitano S.
        • et al.
        Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer.
        Curr Med Chem. 2014; 21: 1639-1653
        • Sharp G.S.
        • Benefiel W.W.
        5-Fluorouracil in the treatment of inoperable carcinoma of the colon and rectum.
        Cancer Chemother Rep. 1962; 20: 97-101
        • Sugimoto Y.
        • Ohe Y.
        • Nishio K.
        • et al.
        In vitro enhancement of fluoropyrimidine-induced cytotoxicity by leucovorin in colorectal and gastric carcinoma cell lines but not in non–small-cell lung carcinoma cell lines.
        Cancer Chemother Pharmacol. 1992; 30: 417-422
        • Salonga D.
        • Danenberg K.D.
        • Johnson M.
        • et al.
        Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.
        Clin Cancer Res. 2000; 6: 1322-1327
        • Leichman L.
        • Lenz H.J.
        • Leichman C.G.
        • et al.
        Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial.
        Eur J Cancer. 1995; 31A: 1306-1310
        • Leichman C.G.
        • Lenz H.J.
        • Leichman L.
        • et al.
        Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin.
        J Clin Oncol. 1997; 15: 3223-3229
        • Qiu L.X.
        • Tang Q.Y.
        • Bai J.L.
        • et al.
        Predictive value of thymidylate synthase expression in advanced colorectal cancer patients receiving fluoropyrimidine based chemotherapy: evidence from 24 studies.
        Int J Cancer. 2008; 123: 2384-2389
        • Subbarayan P.R.
        • Sarkar M.
        • Nelson G.
        • et al.
        Chronic exposure of colorectal cancer cells in culture to fluoropyrimidine analogs induces thymidylate synthase and suppresses p53. A molecular explanation for the mechanism of 5-FU resistance.
        Anticancer Res. 2010; 30: 1149-1156
        • Fukushima M.
        • Sakamoto K.
        • Ohshimo H.
        • et al.
        Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase.
        Oncol Rep. 2010; 24: 835-842
        • Yeh K.H.
        • Cheng A.L.
        • Wan J.P.
        • et al.
        Down-regulation of thymidylate synthase expression and its steady-state mRNA by oxaliplatin in colon cancer cells.
        Anticancer Drugs. 2004; 15: 371-376
        • Hofheinz R.
        • Hartung G.
        • Samel S.
        • et al.
        Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer—a phase II study.
        Anticancer Drugs. 2002; 13: 999-1004
        • Graeven U.
        • Arnold D.
        • Reinacher-Schick A.
        • et al.
        A randomised phase II study of irinotecan in combination with 5-FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma.
        Onkologie. 2007; 30: 169-174
        • de Gramont A.
        • Vignoud J.
        • Tournigand C.
        • et al.
        Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer.
        Eur J Cancer. 1997; 33: 214-219
        • André T.
        • Louvet C.
        • Raymond E.
        • et al.
        Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen.
        Ann Oncol. 1998; 9: 1251-1253
        • André T.
        • Bensmaine M.A.
        • Louvet C.
        • et al.
        Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
        J Clin Oncol. 1999; 17: 3560-3568
        • Cassidy J.
        • Clarke S.
        • Díaz-Rubio E.
        • et al.
        XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results.
        Br J Cancer. 2011; 105: 58-64
        • Montagnani F.
        • Chiriatti A.
        • Turrisi G.
        • et al.
        A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity.
        Colorectal Dis. 2011; 13: 846-852
        • Alagoz M.
        • Gilbert D.C.
        • El-Khamisy S.
        • et al.
        DNA repair and resistance to topoisomerase I inhibitors: mechanisms, biomarkers and therapeutic targets.
        Curr Med Chem. 2012; 19: 3874-3885
        • Petitprez A.
        • Larsen A.K.
        Irinotecan resistance is accompanied by upregulation of EGFR and Src signaling in human cancer models.
        Curr Pharm Des. 2013; 19: 958-964
        • Cunningham D.
        • Humblet Y.
        • Siena S.
        • et al.
        Cetuximab mono-therapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
        N Engl J Med. 2004; 351: 337-345
        • Souglakos J.
        • Kalykaki A.
        • Vamvakas L.
        • et al.
        Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy.
        Ann Oncol. 2007; 18: 305-310
        • Balin-Gauthier D.
        • Delord J.P.
        • Pillaire M.J.
        • et al.
        Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation.
        Br J Cancer. 2008; 98: 120-128
        • Benvenuti S.
        • Sartore-Bianchi A.
        • Di Nicolantonio F.
        • et al.
        Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.
        Cancer Res. 2007; 67: 2643-2648
        • De Roock W.
        • Claes B.
        • Bernasconi D.
        • et al.
        Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
        Lancet Oncol. 2010; 11: 753-762
        • Perrone F.
        • Lampis A.
        • Orsenigo M.
        • et al.
        PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients.
        Ann Oncol. 2009; 20: 84-90
        • Bokemeyer C.
        • Van Cutsem E.
        • Rougier P.
        • et al.
        Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials.
        Eur J Cancer. 2012; 48: 1466-1475
        • Douillard J.Y.
        • Rong A.
        • Sidhu R.
        RAS mutations in colorectal cancer.
        N Engl J Med. 2013; 369: 2159-2160
        • Di Nicolantonio F.
        • Martini M.
        • Molinari F.
        • et al.
        Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
        J Clin Oncol. 2008; 26: 5705-5712
        • Leto S.M.
        • Trusolino L.
        Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies.
        J Mol Med (Berl). 2014; 92: 709-722
        • Giampieri R.
        • Scartozzi M.
        • Del Prete M.
        • et al.
        Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation.
        Crit Rev Oncol Hematol. 2013; 88: 272-283
        • Jeong W.J.
        • Cha P.H.
        • Choi K.Y.
        Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer.
        World J Gastroenterol. 2014; 20: 9862-9871
        • Bardelli A.
        • Siena S.
        Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.
        J Clin Oncol. 2010; 28: 1254-1261
        • Montagut C.
        • Dalmases A.
        • Bellosillo B.
        • et al.
        Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer.
        Nat Med. 2012; 18: 221-223
        • Troiani T.
        • Napolitano S.
        • Vitagliano D.
        • et al.
        Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition.
        Clin Cancer Res. 2014; 20: 3775-3786
        • Van Emburgh B.O.
        • Sartore-Bianchi A.
        • Di Nicolantonio F.
        • et al.
        Acquired resistance to EGFR-targeted therapies in colorectal cancer.
        Mol Oncol. 2014; 8: 1084-1094
        • Crowley E.
        • Di Nicolantonio F.
        • Loupakis F.
        • et al.
        Liquid biopsy: monitoring cancer-genetics in the blood.
        Nat Rev Clin Oncol. 2013; 10: 472-484
        • Ciombor K.K.
        • Berlin J.
        Targeting metastatic colorectal cancer—present and emerging treatment options.
        Pharmgenomics Pers Med. 2014; 7: 137-144
        • Bagri A.
        • Berry L.
        • Gunter B.
        • et al.
        Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy.
        Clin Cancer Res. 2010; 16: 3887-3900
        • Mautner V.F.
        • Nguyen R.
        • Knecht R.
        • et al.
        Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: sustain under continuous drug application and rebound after drug discontinuation.
        Ann Oncol. 2010; 21: 2294-2295
        • Mancuso M.R.
        • Davis R.
        • Norberg S.M.
        • et al.
        Rapid vascular regrowth in tumors after reversal of VEGF inhibition.
        J Clin Invest. 2006; 116: 2610-2621
        • Powles T.
        • Kayani I.
        • Sharpe K.
        • et al.
        A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer.
        Ann Oncol. 2013; 24: 2098-2103
        • Roberts D.L.
        • Williams K.J.
        • Cowen R.L.
        • et al.
        Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells.
        Br J Cancer. 2009; 101: 1290-1297
        • Han X.X.
        • Guo C.M.
        • Li Y.
        • et al.
        Effects of bevacizumab on the neovascular membrane of proliferative diabetic retinopathy: reduction of endothelial cells and expressions of VEGF and HIF-1α.
        Mol Vis. 2012; 18: 1-9
        • Mésange P.
        • Poindessous V.
        • Sabbah M.
        • et al.
        Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor.
        Oncotarget. 2014; 5: 4709-4721
        • Capdevila J.
        • Carrato A.
        • Tabernero J.
        • et al.
        What could nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer?.
        Crit Rev Oncol Hematol. 2014; 92: 83-106
        • Bocci G.
        • Loupakis F.
        The possible role of chemotherapy in antiangiogenic drug resistance.
        Med Hypotheses. 2012; 78: 646-648
        • Wu Y.
        • Lucia K.
        • Lange M.
        • et al.
        Hypoxia inducible factor-1 is involved in growth factor, glucocorticoid and hypoxia mediated regulation of vascular endothelial growth factor-A in human meningiomas.
        J Neurooncol. 2014; 119: 263-273
        • Maughan T.S.
        • James R.D.
        • Kerr D.J.
        • et al.
        Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicenter randomized trial.
        Lancet. 2003; 361: 457-464
        • Adams R.A.
        • Meade A.M.
        • Seymour M.T.
        • et al.
        Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase III MRC COIN trial.
        Lancet Oncol. 2011; 12: 642-653
        • Berry S.R.
        • Cosby R.
        • Asmis T.
        • et al.
        Continuous versus intermittent chemotherapy strategies in metastatic colorectal cancer: a systematic review and meta-analysis.
        Ann Oncol. 2015; 26: 477-485
        • Labianca R.
        • Sobrero A.
        • Isa L.
        • et al.
        Intermittent versus continuous chemotherapy in advanced colorectal cancer : a randomized GISCAD trial.
        Ann Oncol. 2011; 22: 1236-1242
        • Aprile G.
        • Mazzer M.
        • Moroso S.
        • et al.
        Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer.
        Anticancer Drugs. 2009; 20: 217-229
        • Tournigand C.
        • Cervantes A.
        • Figer A.
        • et al.
        OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer. A GERCOR study.
        J Clin Oncol. 2006; 24: 394-400
        • Chibaudel B.
        • Maindrault-Goebel F.
        • Lledo G.
        • et al.
        Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 study.
        J Clin Oncol. 2009; 27: 5727-5733
        • Saltz L.B.
        • Clarke S.
        • Díaz-Rubio E.
        • et al.
        Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
        J Clin Oncol. 2008; 26: 2013-2019
        • Hochster H.S.
        • Grothey A.
        • Hart L.
        • et al.
        Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT.
        Ann Oncol. 2014; 25: 1172-1178
        • Díaz-Rubio E.
        • Gómez-España A.
        • Massutí B.
        • et al.
        First-line XELOX plus bevacizumab followes by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.
        Oncologist. 2012; 17: 15-25
        • Simkens L.H.
        • van Tinteren H.
        • May A.
        • et al.
        Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
        Lancet. 2015; 385: 1843-1852
        • Hegewisch-Becker S.
        • Graeven U.
        • Lerchenmüller C.A.
        • et al.
        Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
        Lancet Oncol. 2015; (pii: S1470-2045(15)00042-X)
        • Koeberle D.
        • Betticher D.C.
        • Von Moos R.
        • et al.
        Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: a randomized phase III non inferiority trial (SAKK 41/06).
        J Clin Oncol. 2013; (abstract 3503)
        • Pereira A.A.L.
        • Rego J.F.M.
        • Hoff P.M.
        • et al.
        The effect of chemotherapy delivered until progression versus complete stop on the overall survival of patients with metastatic colorectal cancer: a meta-analysis of randomized trials.
        J Clin Oncol. 2014; 32: 3542
        • Aprile G.
        • Macerelli M.
        • Giuliani F.
        Regorafenib for gastrointestinal malignancies: from preclinical data to clinical results of a novel multi-target inhibitor.
        BioDrugs. 2013; 27: 213-224
        • Martinelli E.
        • Troiani T.
        • Venturini F.
        • et al.
        Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).
        J Clin Oncol. 2015; 33 (abstract TPS789)
        • Mendelsohn J.
        • Baselga J.
        Epidermal growth factor receptor targeting in cancer.
        Semin Oncol. 2006; 33: 369-385
        • Wasan H.
        • Meade A.M.
        • Adams R.
        • et al.
        Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial.
        Lancet Oncol. 2014; 15: 631-639
        • Bianco R.
        • Garofalo S.
        • Rosa R.
        • et al.
        Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs.
        Br J Cancer. 2008; 98: 923-930
        • Loupakis F.
        • Cremolini C.
        • Fontanini G.
        • et al.
        Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer.
        Ther Adv Med Oncol. 2009; 1: 167-181
        • Giampieri R.
        • Aprile G.
        • Del Prete M.
        • et al.
        Beyond RAS: the role of epidermal growth factor receptor (EGFR) and its network in the prediction of clinical outcome during anti-EGFR treatment in colorectal cancer patients.
        Curr Drug Targets. 2014; 15: 1225-1230
        • Salvatore L.
        • Loupakis F.
        • Cremolini C.
        • et al.
        Phase II randomized study of induction FOLFOXIRI plus bevacizumab (Bev) followed by maintenance with Bev alone or Bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): the MOMA trial.
        J Clin Oncol. 2014; 32 (abstract TPS3664)
      1. ERbitux MEtastatic colorectal cancer Strategy Study: a phase III randomized two arm study with FOLFIRI + cetuximab until disease progression compared to FOLFIRI + cetuximab for 8 cycles followed by cetuximab alone until disease progression in first line treatment of patients with RAS and BRAF wild type metastatic colorectal cancer [EudraCT no. 2014-004299-41]. Available at:–004299–41/IT. Accessed: April 12, 2015.

        • Naumov G.N.
        • Nilsson M.B.
        • Cascone T.
        • et al.
        Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
        Clin Cancer Res. 2009; 15: 3484-3494
        • Saltz L.B.
        • Lenz H.J.
        • Kindler H.L.
        • et al.
        Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared to cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.
        J Clin Oncol. 2007; 25: 4557-4561
        • Tournigand C.
        • Chibaudel B.
        • Samson B.
        • et al.
        Maintenance therapy with bevacizumab with or without erlotinib in metastatic colorectal cancer (mCRC) according to k-ras status: results of the GERCOR DREAM phase III trial.
        J Clin Oncol. 2013; (abstract 3515)
        • Schmoll H.J.
        • Wittig B.
        • Arnold D.
        • et al.
        Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial.
        J Cancer Res Clin Oncol. 2014; 140: 1615-1624
        • Schmoll H.J.
        • Riera-Knorrenschild J.
        • Kopp H.G.
        • et al.
        Maintenance therapy with the TLR-9 agonist MGN1703 in the phase II IMPACT study of metastatic colorectal cancer patients: a subgroup with improved overall survival.
        J Clin Oncol. 2015; 33 (abstract 680)
        • Cunningham D.
        • Zurlo A.
        • Salazar R.
        • et al.
        IMPALA, a randomized phase III study in patients with metastatic colorectal carcinoma: immunomodulatory maintenance therapy with TLR-9 agonist MGN1703.
        J Clin Oncol. 2015; 33 (abstract TPS791)
        • Zou B.
        • Qiao L,Wong B.C.
        Current understanding of the role of PPARγ in gastrointestinal cancers.
        PPAR Res. 2009; 2009: 816957
        • Komatsu Y.
        • Yoshino T.
        • Yamazaki K.
        • et al.
        Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
        Invest New Drugs. 2014; 32: 473-480
        • Boucher E.
        • Davidenko I.
        • Hadler I.
        • et al.
        Randomised, placebo-controlled, phase 2 study of efatutazone maintenance therapy in patients with advanced colorectal cancer who have achieved disease control following first-line chemotherapy.
        Paper presented at: World Congress on Gastrointestinal Cancers, Barcelona, Spain25-28 June, 2014
        • Lien K.
        • Georgsdottir S.
        • Sivanathan L.
        • et al.
        Low-dose metronomic chemotherapy: a systematic literature analysis.
        Eur J Cancer. 2013; 49: 3387-3395
        • Hao Y.B.
        • Yi S.Y.
        • Ruan J.
        • et al.
        New insights into metronomic chemotherapy–induced immunoregulation.
        Cancer Lett. 2014; 354: 220-226
        • André N.
        • Carré M.
        • Pasquier E.
        Metronomics: towards personalized chemotherapy?.
        Nat Rev Clin Oncol. 2014; 11: 413-431
        • Gnoni A.
        • Silvestris N.
        • Licchetta A.
        • et al.
        Metronomic chemotherapy from rationale to clinical studies: a dream or reality?.
        Crit Rev Oncol Hematol. 2015; 95: 46-61
        • Bocci G.
        • Nicolaou K.C.
        • Kerbel R.S.
        Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs.
        Cancer Res. 2002; 62: 6938-6943
        • Louvet C.
        • Coudray A.M.
        • Tournigand C.
        • et al.
        Synergistic antitumoral activity of combined UFT, folinic acid and oxaliplatin against human colorectal HT29 cell xenografts in athymic nude mice.
        Anticancer Drugs. 2000; 11: 579-582
        • Tsujimoto H.
        • Tsukioka S.
        • Ono S.
        • et al.
        Effect of leucovorin on the antitumor efficacy of the 5-FU prodrug, tegafur–uracil, in human colorectal cancer xenografts with various expression levels of thymidylate synthase.
        Oncol Lett. 2010; 1: 973-980
        • Kolinsky K.
        • Shen B.Q.
        • Zhang Y.E.
        • et al.
        In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancerxenograft models.
        Mol Cancer Ther. 2009; 8: 75-82
        • Hackl C.
        • Man S.
        • Francia G.
        • et al.
        Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models.
        Gut. 2013; 62: 259-271
        • Petrioli R.
        • Pascucci A.
        • Francini E.
        • et al.
        Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors.
        Anticancer Drugs. 2008; 19: 91-96
        • Nannini M.
        • Nobili E.
        • Di Cicilia R.
        • et al.
        To widen the setting of cancer patients who could benefit from metronomic capecitabine.
        Cancer Chemother Pharmacol. 2009; 64: 189-193
        • Kelley R.K.
        • Hwang J.
        • Magbanua M.J.
        • et al.
        A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer.
        Br J Cancer. 2013; 109: 1725-1734
        • Pietrantonio F.
        • Biondani P.
        • Pellegrinelli A.
        • et al.
        Hepatic colorectal cancer metastases showing a distinctive pattern of pathological response after metronomic capecitabine and bevacizumab.
        Med Oncol. 2012; 29: 2838-2841
        • Norrby K.
        Metronomic chemotherapy and anti-angiogenesis: can upgraded pre-clinical assays improve clinical trials aimed at controlling tumor growth?.
        APMIS. 2014; 122: 565-579
        • Jagsi R.
        • Sulmasy D.P.
        • Moy B.
        Value of cancer care: ethical considerations for the practicing oncologist.
        Am Soc Clin Oncol Educ Book. 2014; : e146-e149
        • Carter H.E.
        • Zannino D.
        • John Simes R.
        • et al.
        The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: results from the Australasian phase III MAX study.
        Eur J Cancer. 2014; 50: 535-543
        • Whyte S.
        • Pandor A.
        • Stevenson M.
        Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal.
        Pharmacoeconomics. 2012; 30: 1119-1132
        • Lange A.
        • Prenzler A.
        • Frank M.
        • et al.
        A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer.
        Eur J Cancer. 2014; 50: 40-49
        • Lawrence D.
        • Maschio M.
        • Leahy K.J.
        • et al.
        Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC).
        J Med Econ. 2013; 16: 1387-1398
        • Ewara E.M.
        • Zaric G.S.
        • Welch S.
        • et al.
        Cost-effectiveness of first-line treatments for patients with KRAS wild-type metastatic colorectal cancer.
        Curr Oncol. 2014; 21: e541-e550
        • Shankaran V.
        • Mummy D.
        • Koepl L.
        • et al.
        Survival and lifetime costs associated with first-line bevacizumab use in older patients with metastatic colorectal cancer.
        Oncologist. 2014; 19: 892-899
        • Díaz-Rubio E.
        • Pietrantonio F.
        • de Braud F.
        Continuing single-agent bevacizumab as maintenance therapy after induction XELOX (or FOLFOX) plus bevacizumab in first-line treatment of metastatic colorectal cancer.
        Oncologist. 2012; 17: 1426-1428
        • Fasola G.
        • Aprile G.
        • Marini L.
        • et al.
        Drug waste minimization as an effective strategy of cost-containment in oncology.
        BMC Health Serv Res. 2014; 14: 57
        • Francis S.M.
        • Heyliger A.
        • Miyares M.A.
        • et al.
        Potential cost savings associated with dose rounding antineoplastic monoclonal agents.
        J Oncol Pharm Practice. 2015; 21: 280-284
        • Neumann P.J.
        • Cohen J.T.
        • Weinstein M.C.
        Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold.
        N Engl J Med. 2014; 371: 796-797
        • Lipscomb J.
        • Yabroff K.R.
        • Hornbrook M.C.
        • et al.
        Comparing cancer care, outcomes, and costs across health systems: charting the course.
        J Natl Cancer Inst Monogr. 2013; 2013: 124-130
        • Sobrero A.
        • Bruzzi P.
        Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval.
        J Clin Oncol. 2009; 27: 5868-5873